Eugenia Chock, MD, MPH
Assistant Professor of Medicine (Rheumatology, Allergy & immunology)
Research & Publications
Biography
News
Coauthors
Selected Publications
- Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report.Barbhaiya M, Taghavi M, Zuily S, Domingues V, Chock EY, Tektonidou MG, Erkan D, Seshan SV, New APS Classification Criteria Steering Committee and APS ACTION Collaborators. Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. J Rheumatol 2024, 51: 150-159. PMID: 37399462, DOI: 10.3899/jrheum.2022-1200.
- Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) RegistryPine A, Butt A, Garcia-Milian R, Gu S, Restrepo V, Chock Y, Hwa J, Tormey C, Rinder H, Goshua G, Belmont H, Bertolaccini M, Branch D, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee A, Sharda A. Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Blood 2023, 142: 2575. DOI: 10.1182/blood-2023-185232.
- Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping reviewChock E, Dahal S, Grimshaw A, Suter L, Liew Z, Felson D. Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review. Seminars In Arthritis And Rheumatism 2023, 61: 152230. PMID: 37295300, PMCID: PMC10521166, DOI: 10.1016/j.semarthrit.2023.152230.
- Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, Sartelet H, Erkan D, Wahl D, Zuily S. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev 2022, 21: 103158. PMID: 35907609, DOI: 10.1016/j.autrev.2022.103158.
- Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine SurveyDiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.
- Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international surveyChock EY, Putman M, Conway R, Danila MI, Hoyer B, Hsieh E, Jayatilleke A, Kilian A, Leipe J, Liew JW, Machado PM, Robinson PC, Singh N, Ung N, Yeoh SA, Wallace ZS, Grainger R, Cappelli LC. Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international survey. Rheumatology Advances In Practice 2022, 6: rkac039. PMID: 35669677, PMCID: PMC9154733, DOI: 10.1093/rap/rkac039.
- Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseasesHausmann J, Kennedy K, Simard J, Liew J, Sparks J, Moni T, Harrison C, Larché M, Levine M, Sattui S, Semalulu T, Foster G, Surangiwala S, Thabane L, Beesley R, Durrant K, Mateus E, Mingolla S, Nudel M, Palmerlee C, Richards D, Liew D, Hill C, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Sirotich E, Alliance C, Robinson P, Bhana S, Liew J, Sufka P, Singh N, Howard R, Kim A, Westrich-Robertson T, Sirotich E, Tsui E, Duarte-Garcia A, Sparks J, Tam H, Jayatilleke A, Konig M, Graef E, Putman M, Syed R, Korsten P, Mateus E, Sattui S, Wallace Z, Laura U, Adam K, Chock Y, White D, Zamora G, Traboco L, Patel A, Grainger R, Ugarte-Gil M, Gianfrancesco M, Amigues I, Sanchez-Alvarez C, Trupin L, Jacobsohn L, Beesley R, Hoyer B, Machado P, Makan K, Gossec L, Priyank C, Leipe J, Wallace B, Angeles-Han S, Almaghlouth I, Katherine W, Padula A, Berenbaum F, Treemarcki E, Sinha R, Lewandowski L, Webb K, Young K, Bulina I, Uribe S, Rubinstein T, Nolan M, Ang E, Venuturupalli S, Hausmann J, Dubreuil M, Pisoni C, Cosatti M, Campos J, Simard J, Conway R, Peterson T, Harrison C, Felix C, Richards D, Proulx L, Akpabio A, Worthing A, Laidlaw L, Reid P, Palmerlee C, Danila M, Sahar L, Linh N, Agarwal A, Studenic P, Liew D, Larche M, Mingolla S, Zamora E, Angevare S, Sinha R, Durrant K, Peirce A, Somers E, Cappelli L, Frankel B, Kumar B, Krupnikova S, Vega J, Frankovich J, Fernandez-Ruiz R, Velásquez M, Yeoh S, Marino M, Nudel M, Scott C, Rodríguez C, Mancheño A, Seo P, Gamboa-Cárdenas R, Pimentel-Quiroz V, Reátegui-Sokolova C, Kihara M, Lin C, Kattula D, Laila G, Carmona L, Wallace J, Yazdany J, Costello W, Gore-massy M, Tomasella L, Kodek M. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. The Lancet Rheumatology 2021, 3: e707-e714. PMID: 34316727, PMCID: PMC8298011, DOI: 10.1016/s2665-9913(21)00175-2.
- Corrigendum to “Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis” [AUTREV 18–11 (2019) 102395]Chock Y, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Corrigendum to “Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis” [AUTREV 18–11 (2019) 102395]. Autoimmunity Reviews 2020, 19: 102503. PMID: 32165134, DOI: 10.1016/j.autrev.2020.102503.
- AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritisChock Y, Danve A, School of Medicine O, Petri M, Fu W. AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis. Annals Of The Rheumatic Diseases 2018, 77: 1425. DOI: 10.1136/annrheumdis-2018-eular.4524.
Clinical Trials
Conditions | Study Title |
---|---|
Immune System | Yale Lupus and Connective Tissue Disease Bio-Repository / Yale Rheumatology Bio-Repository |
Arthritis | Yale Rheumatology Program Patient Registry and Bio-Repository |